IVT RNA Manufacturing Process with Optimized Buffer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for in vitro transcription (IVT) of RNA, particularly for longer self-amplyfing mRNAs with high secondary structures, face challenges in achieving high yield and maintaining RNA integrity due to inefficiencies in manufacturing processes.

Innovation Solution

The use of specific reaction buffer compositions with magnesium ions (Mg2+) at concentrations ranging from 16-50 mM and nucleotide triphosphates (NTPs) at concentrations of 20-52 mM, optimized to enhance RNA yield and quality, along with capping the 5' end of the RNA for stability and translational efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional IVT protocols are used with standard Mg2+ and NTP concentrations, then the manufacturing process is simple and follows established procedures, but the RNA yield is insufficient for longer mRNAs with high secondary structures

Engineering Contradiction:

ImproveRNA yieldVSAvoidreaction buffer composition complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by optimizing the concentrations of Mg2+ (16-50 mM) and NTPs (20-52 mM) in the reaction buffer to significantly improve RNA yield for longer mRNAs with high secondary structures, while maintaining a relatively simple buffer system without requiring complex additional components

Inventive Principle:

Principle #35Parameter changes

2Productivity

If higher Mg2+ and NTP concentrations are used to improve RNA yield, then transcription efficiency increases, but the risk of non-specific reactions and RNA degradation increases

Engineering Contradiction:

Improvetranscription efficiencyVSAvoidRNA integrity

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent optimizes parameter ranges for Mg2+ (16-50 mM) and NTPs (20-52 mM) to achieve high transcription efficiency while maintaining RNA integrity, representing a balanced parameter optimization that prevents both insufficient yield and excessive non-specific reactions

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs pyrophosphatase in the reaction buffer to degrade accumulated pyrophosphate, creating a feedback mechanism that prevents pyrophosphate inhibition of transcription and maintains reaction reliability throughout the transcription process

Inventive Principle:

Principle #23Feedback

3Adaptability or versatility

If longer mRNAs are synthesized to achieve self-amplifying functionality, then vaccine efficacy is improved, but transcription efficiency and RNA integrity deteriorate due to secondary structures

Engineering Contradiction:

Improveself-amplifying capabilityVSAvoidtranscription efficiency

Core Design Contradiction:

Adaptability or versatilityVSProductivity

Solution Approach 1:

The patent uses elevated Mg2+ (16-50 mM) and NTP (20-52 mM) concentrations to overcome the transcription inefficiencies caused by secondary structures in longer self-amplifying mRNAs, enabling successful synthesis of functional vaccine candidates

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent incorporates pyrophosphatase to continuously degrade pyrophosphate during transcription, preventing accumulation that would otherwise inhibit transcription and ensuring continuous productive transcription of long mRNA sequences

Inventive Principle:

Principle #20Continuity of useful action

4Ease of manufacture

If RNA is produced without 5' end capping to simplify the process, then manufacturing steps are reduced, but RNA stability and translational efficacy decrease

Engineering Contradiction:

Improvemanufacturing process simplicityVSAvoidRNA stability

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent performs 5' end capping as a preliminary stabilization step to protect the RNA from degradation and enhance translational efficacy, ensuring RNA stability is established before subsequent manufacturing and formulation steps

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach significantly improves RNA yield and quality, ensuring high integrity and stability, particularly for longer mRNAs, by optimizing magnesium and NTP concentrations and incorporating capping processes, thereby addressing the inefficiencies in existing IVT methods.

Implementation Method 1

an RNA polymerase that requires ribonucleotide triphosphates as RNA building blocks and a buffer system that includes DL-dithiothreitol (DTT) and magnesium ions as a cofactor to RNA polymerase

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 2

pyrophosphatase for degrading accumulated pyrophosphate

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 3

a ribonuclease inhibitor for inactivating RNase activity

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Data Source

PatentUS20240352496A1IVT RNA manufacturing process

Publication Date: 2024.10.24 GLAXOSMITHKLINE BIOLOGICALS SA

AI summary

Improved methods for manufacturing a RNA by IVT and compositions for use therein are provided.